Collaboration Opportunities with Daiichi Sankyo in Early Stage Research and Technology

Registration is now closed. Please email tony@onenucleus.com to be added to the waitlist.

Daiichi Sankyo, the global pharmaceutical company with corporate origins in Japan is seeking research collaborations with UK entities in a number of key areas. One Nucleus is delighted to be working with Daiichi Sankyo and the Department for International Trade Japan Team to bring you a free online seminar to enable you to learn about the Daiichi Sankyo research priorities and collaboration structures available. The core areas of interest include:

• Novel modality technologies in oncology and CNS (psychiatric and neurodegenerative disease)
  • Ex) Target protein degrader (except E3 binder), conditional active antibody (except pH-dependent), next generation of gene therapy etc
• Novel drug delivery technologies to cancer cells or brain after systemic administration
  • Ex) Engineered nanoparticle/exosome etc
• Novel target or cancer-specific antigen for antibody in oncology

Speaker
Kunihiko Fujii, Manager, BD & Licensing, Daiichi Sankyo

Registration is free and the limited places will be allocated on a first-come-first-served basis.

Please note, all registrations are subject to the approval of the sponsor.  You will be informed if your registration has been unsuccessful within 2 working days of registering online for the event.